International Federation of Pharmaceutical Manufacturers and Associations Calls for AI Use in Regulatory Activities

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has released a report on the use of artificial intelligence technologies in regulatory activities, such as drug licensing and oversight, emphasizing the need to establish global standards and ethical principles in this field.

The text published by the IFPMA states that scientific innovation is transforming drug development processes and that artificial intelligence can enhance regulatory capacity in the analysis of this complex data. The pharmaceutical industry argues that AI-supported approaches can increase efficiency while maintaining trust and rigor in regulatory decisions.

It is stated that national regulatory authorities are evaluating the use of artificial intelligence in areas such as internal operations, documentation, product reviews, and inspections. The federation notes that global harmonization in terminology and strategies is essential to prevent these technologies from creating a fragmented structure, which could accelerate drug development processes.